Mikołaj Słabicki
- Molecular Biology top 10%
- Ubiquitin and proteasome pathways 9
- Protein Degradation and Inhibitors 8
- RNA Research and Splicing 3
- Genomics and Chromatin Dynamics 3
- Oncology top 10%
- CAR-T cell therapy research 3
- Cancer-related Molecular Pathways 3
- Cancer Research top 10%
- Hematology top 10%
- Acute Myeloid Leukemia Research 2
- Cell Biology top 10%
-
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Benjamin L. EbertQuinlan SieversFrank BuchholzNicolas H. ThomäGeorg PetzoldTarjei S. MikkelsenWassim AbdulrahmanR.D. Bunker
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Mikołaj Słabicki
25 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Molecular Biology 1.1k
- Oncology 415
- Cancer Research 216
- Hematology 134
- Cell Biology 160
Countries citing papers authored by Mikołaj Słabicki
This map shows the geographic impact of Mikołaj Słabicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikołaj Słabicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikołaj Słabicki more than expected).
Fields of papers citing papers by Mikołaj Słabicki
This network shows the impact of papers produced by Mikołaj Słabicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikołaj Słabicki. The network helps show where Mikołaj Słabicki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mikołaj Słabicki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 9 | |
| 3 | 2023 | 54 | |
| 4 | 2023 | 7 | |
| 5 | 2023 | 30 | |
| 6 | 2022 | 4 | |
| 7 | 2022 | 18 | |
| 8 | 2022 | 9 | |
| 9 | 2021 | 180 | |
| 10 | 2020 | 11 | |
| 11 | Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBNbreakdown → | 2018 | 341 |
| 12 | 2017 | 27 | |
| 13 | 2015 | 140 | |
| 14 | 2014 | 3 | |
| 15 | 2011 | 63 | |
| 16 | 2010 | 7 | |
| 17 | 2009 | 76 | |
| 18 | 2007 | 233 | |
| 19 | 2006 | 52 | |
| 20 | 2004 | 2 |
About Mikołaj Słabicki
Mikołaj Słabicki is a scholar working on Molecular Biology, Hematology and Cell Biology, having authored 26 papers that have together received 1.4k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (9 papers), Protein Degradation and Inhibitors (8 papers), CAR-T cell therapy research (3 papers), Cancer-related Molecular Pathways (3 papers), RNA Research and Splicing (3 papers), Genomics and Chromatin Dynamics (3 papers), Acute Myeloid Leukemia Research (2 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). The work is most often cited by research in Molecular Biology (1.1k citations), Oncology (415 citations) and Cancer Research (216 citations). Mikołaj Słabicki has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Benjamin L. Ebert, Quinlan Sievers, Frank Buchholz, Nicolas H. Thomä, Georg Petzold, Tarjei S. Mikkelsen, Wassim Abdulrahman, R.D. Bunker, Aline Renneville and Brian Liddicoat.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.